FLT3 and acute myeloid leukemia: To illustrate the mechanism responsible for the relapse of FLT3-mut AML in vitro and identify the potential biomarkers of TKI-resistant blasts, we performed detailed analyses of TKI-treated blasts at different time intervals (3 days, 10 days, 20 days, and 28 days) after exposure to TKIs.